Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of
600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza
infection and in subjects with acute uncomplicated influenza infection at higher risk for
influenza complications. All subjects will receive IV peramivir.